Just caught that Soleno Therapeutics made a leadership move - Jennifer Fulk is stepping in as their new CFO. Pretty solid hire if you ask me, given her background. She was running ops and finance at 120Water not too long ago, and before that spent a few years as CFO over at Talkspace. But what caught my eye is the Eli Lilly experience - over 15 years in finance roles there, including heading up U.S. Bio-Medicines. That's the kind of pharma pedigree you want when you're focused on rare disease treatments. Fulk takes over from James Mackaness, who's heading out by end of Q1. Interesting to see how she'll shape the financial strategy for a rare disease therapeutics company. Anyone following Soleno's pipeline?